The accuracy of the American Heart Association calculator for predicting 10 year risk is not improved by adding Lp(a).
Quoted:
“In parallel with improvements in risk scores, there has been an unending search for blood-based biomarkers that may add predictive utility to existing risk equations. Many such biomarkers have demonstrated independent associations with ASCVD events, but have fallen short with regard to demonstrating incremental predictive utility, precluding recommendations for universal screening or routine incorporation into risk equation platforms.”
“In this issue of JAMA Cardiology, Bhatia et al evaluate the predictive utility of adding lipoprotein(a) (Lp[a]) level, a blood-based biomarker consistently linked to ASCVD risk, to the PREVENT equations.”
“With regard to predictive utility, Lp(a) did not change C statistics significantly and it had very modest ability to reclassify predicted risk appropriately, as evidenced by the continuous and categorical net reclassification improvements.”





